Reported about 5 hours ago
Pfizer's COVID-19 vaccine sales have dropped by 25% following the U.S. government's recent narrowing of recommendations for vaccinations. The delay in approving updated shots has further impacted sales, as interest in COVID-19 vaccinations wanes amid rising anti-vaccine sentiments and confusion over the necessity of the shots. As a result, sales of Pfizer's Comirnaty vaccine fell to $870 million in the last quarter, down from $1.16 billion a year prior. Experts warn that vaccination rates could continue to decline this season.
Source: YAHOO